Evidence map›Paper›PMID 28800074›Full record

ArticleInternational journal of molecular sciences2017

Phellinus linteus Grown on Germinated Brown Rice Increases Cetuximab Sensitivity of KRAS-Mutated Colon Cancer.

Hye-Jin Park, Jeong-Bin Park, Sang-Jae Lee, Minjung Song

Open access · goldAbstract read
In one paragraph

Article in International journal of molecular sciences, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.1field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 24 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Article
  6. Active Compound ofMolecules (Basel, Switzerland) · 2020
    Article
  7. Nutrients · 2019
    Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Hye-Jin ParkDepartment of Food Biotechnology, Gachon University, Kyungji-Do 13120, Korea. nimpi79@hanmail.net.
Jeong-Bin ParkDepartment of Food Biotechnology, Division of Bioindustry, Silla University, Busan 46958, Korea. parkjb928@daum.net.
Sang-Jae LeeDepartment of Food Biotechnology, Division of Bioindustry, Silla University, Busan 46958, Korea. sans76@silla.ac.kr.
Minjung SongDepartment of Food Biotechnology, Division of Bioindustry, Silla University, Busan 46958, Korea. songmj@silla.ac.kr.
Silla University · KRGachon University · KR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Colon cancer is one of the most common types of cancer, and it has recently become a leading cause of death worldwide. Among colon cancers, the v-ki-ras2 Kirsten rat sarcoma viral oncogene homolog (KRAS)-mutated form is notorious for its non-druggable features. Cetuximab, a monoclonal antibody that binds to the epidermal growth factor receptor, has been introduced as an antitumor therapy; however, secondary resistance and side effects significantly limit its effective use in these cancers. In this study, we prepared

Indexed as

AnimalsAntineoplastic AgentsApoptosisBasidiomycotaBiological ProductsCell ExtractsCell ProliferationCetuximabColonic NeoplasmsDrug Resistance, NeoplasmDrug SynergismHT29 CellsHumansMaleMiceMice, NudeAntineoplastic AgentsBiological ProductsCell ExtractsCetuximabProto-Oncogene Proteins p21(ras)cetuximabcolorectal cancerdrug sensitivityKirsten rat sarcoma viral oncogene homologPhellinuslinteusβ-glucan

Identifiers

PMID28800074
PMCPMC5578136
OpenAlexW2744161612

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.